Outcomes of Patients Who Develop Bacteremia in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis

Key Points

• Bacteremia significantly impacts outcomes in patients after transplant, highlighting urgent clinical concerns.
• The study tracks patients within the first 100 days post-transplant, focusing on immune response markers and infections.
• Analysis of patients undergoing allogeneic hematopoietic cell transplantation emphasizes the role of post-transplant cyclophosphamide in outcomes.
• These findings suggest the need for enhanced monitoring and management strategies to reduce bacteremia risks post-transplant.